Dosing and switching of paliperidone ER in patients with schizophrenia: Recommendations for clinical practice

Annals of General Psychiatry

Volumn 13, Issue 1, 2014, Pages

  Peuskens, Joseph ^a   Rubio, Gabriel ^b   Schreiner, Andreas ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SCHOOL OF MEDICINE   (Spain)

^c Medical Affairs   (Germany)

Author keywords

Antipsychotic; Dosing; Paliperidone; Schizophrenia; Switching

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GABAPENTIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; ZIPRASIDONE;

AKATHISIA; ANTICHOLINERGIC EFFECT; BODY MASS; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SLEEP QUALITY; WITHDRAWAL SYNDROME;

EID: 84898013303     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-13-10     Document Type: Review

References (77)

1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association Steering Committee on Practice Guidelines: practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-56. American Psychiatric Association.
2. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr 2007, 12:21-26.
3. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007, 68(Suppl 14):27-30.
4. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008, 69(Suppl 1):4-17.
5. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000, 15(Suppl 4):S15-S19.
6. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997, 58(Suppl 10):63-72.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. 10.1056/NEJMoa051688, 16172203, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
8. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009, 113:56-64. 10.1016/j.schres.2009.05.021, 19560322.
9. Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, Awad AG. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 2010, 25:155-164. 10.1097/YIC.0b013e3283372977, 20216424.
10. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995, 10:207-213. 10.1097/00004850-199511000-00001, 8748041.
11. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000, 157:987-993. 10.1176/appi.ajp.157.6.987, 10831481.
12. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual " atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002, 159:180-190. 10.1176/appi.ajp.159.2.180, 11823257.
13. Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat 2008, 4:949-958. 2626923, 19183785.
14. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409. 10.2165/00023210-200620050-00004, 16696579.
15. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564. 10.1001/archpsyc.60.6.553, 12796218.
16. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41. 10.1016/S0140-6736(08)61764-X, 19058842.
17. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007, 21:911-936. 10.2165/00023210-200721110-00004, 17927296.
18. Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsoq P, Salinas R, Theodoropoulou P, Fernández LG, Uçok A, Tessier C, Bergmans P, Hoeben D. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol 2012, 32:449-457. 10.1097/JCP.0b013e31825cccad, 22722501.
19. Gorwood P, Burns T, Juckel G, Rossi A, San L, Hargarter L, Schreiner A, Europe, Middle East and Africa functioning group Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa. Ann Gen Psychiatry 2013, 12:8. 10.1186/1744-859X-12-8, 3778848, 23531356, Europe, Middle East and Africa functioning group.
20. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Assocation for Psychopharmacology. J Psychopharmacol 2011, 25:567-620. 10.1177/0269881110391123, 21292923.
21. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36:71-93. 10.1093/schbul/sbp116, 2800144, 19955390, Schizophrenia Patient Outcomes Research Team (PORT).
22. National Institute for Health & Care Excellence Psychosis and schizophrenia in adults. The NICE guideline on treatment and management. National Clinical Guideline Number CG178. http://www.nice.org.uk/nicemedia/live/14382/66529/66529.pdf. Accessed 24 March 2014, National Institute for Health & Care Excellence.
23. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010, 167:686-693. 10.1176/appi.ajp.2009.09060802, 20360319.
24. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, Hummer M, Fleischhacker WW. Switching between second-generation antipsychotics: why and how?. CNS Drugs 2005, 19:27-42. 10.2165/00023210-200519010-00003, 15651903.
25. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007, 12:904-922. 10.1038/sj.mp.4002062, 17667958.
26. Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther 2010, 48:383-399. 10.5414/CPP48383, 20497747.
27. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004, 26:649-666. 10.1016/S0149-2918(04)90066-5, 15220010.
28. Invega® (paliperidone) prolonged-release tablets [summary of product characteristics] 2013, Buckinghamshire, United Kingdom: Janssen-Cilag Ltd, http://www.medicines.org.uk/emc/medicine/19828/SPC. Accessed 06 February 2014.
29. Risperdal® (risperidone) Tablets, Liquid and Quicklet [summary of product characteristics] 2013, Buckinghamshire, United Kingdom: Janssen-Cilag Ltd, http://www.medicines.org.uk/emc/medicine/12818/SPC/. Accessed 06 February 2014.
30. Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007, 100:4-22. 10.1111/j.1742-7843.2007.00017.x, 17214606.
31. Haldol (haloperidol) tablets [summary of product characteristics] 2013, Buckinghamshire, United Kingdom: Janssen-Cilag Ltd, http://www.medicines.org.uk/emc/medicine/17422/SPC/Haldol+5mg+Tablets/. Accessed 06 February 2014.
32. Olanzapine Accord (olanzapine) 10 mg film-coated tablets [summary of product characteristics] 2012, Middlesex, United Kingdom: Accord Healthcare Limited, http://www.medicines.org.uk/emc/medicine/25894/spc. Accessed 06 February 2014.
33. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:199-204. 10.1016/j.pnpbp.2008.09.026, 18948162.
34. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008, 18:81-98. 10.1089/cap.2007.0084, 18294091.
35. Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RJ. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000, 49(Suppl 1):27S-33S. 2015058, 10771451.
36. Clozaril® (clozarine) 25 mg and 100 mg tablets [summary of product characteristics] 2013, Surrey, United Kingdom: Novartis Pharmaceuticals UK Ltd, http://www.medicines.org.uk/emc/medicine/1277. Accessed 06 February 2014.
37. Abilify (aripiprazole) tablets, orodispersible tablets and oral solution [summary of product characteristics] 2013, Wexham, United Kingdom: Otsuka Pharmaceuticals (UK) Ltd, http://www.medicines.org.uk/emc/medicine/18494/SPC/Abilify+Tablets,+Orodispersible+Tablets,+Oral+Solution/. Accessed 06 February 2014.
38. Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci 2012, 9:17-23.
39. Goren JL, Levin GM. Quetiapine, an atypical antipsychotic. Pharmacotherapy 1998, 18:1183-1194.
40. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing and switching of antipsychotics. Eur Psychiatry 2010, 25(Suppl 2):S12-S21.
41. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence?. Schizophr Res 2005, 76:267-272. 10.1016/j.schres.2005.01.009, 15949658.
42. Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 2008, 6:17. 10.1186/1741-7015-6-17, 2474645, 18590519.
43. Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, Lissens J, Sanchez R. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry 2009, 42:114-121. 10.1055/s-0028-1112134, 19452380.
44. Viguera AC, Baldessarini RJ, Hegarty JD, Van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997, 54:49-55. 10.1001/archpsyc.1997.01830130055011, 9006400.
45. Stahl S. Stahl's Essential Psychopharmacology 2008, Cambridge: Cambridge University Press.
46. Invega® (paliperidone) extended-release tablets [prescribing information] 2014, Titusville, NJ: Janssen Pharmaceuticals Inc, http://www.invega.com/prescribing-information. Accessed 06 February 2014.
47. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 1879-1892, 2006:22.
48. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-130. 10.1016/j.schres.2007.03.003, 17466492.
49. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-161. 10.1016/j.schres.2006.09.012, 17092691.
50. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-1370. 10.1016/j.biopsych.2007.01.017, 17601495.
51. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008, 69:817-829. 10.4088/JCP.v69n0515, 18466043.
52. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009, 166:691-701. 10.1176/appi.ajp.2009.08040613, 19411369.
53. Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008, 23:343-356. 10.1097/YIC.0b013e328314e1f3, 18854723.
54. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007, 27:6-14. 10.1097/JCP.0b013e31802dda4a, 17224706.
55. Schmauss M, Jukić V, Siracusano A, Bidzan L, Badescu GM, Maciulis V, Lahaye M, Hoeben D, Tessier C, Schreiner A. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Curr Med Res Opin 2012, 28:1395-1404. 10.1185/03007995.2012.708327, 22746355.
56. Schreiner A, Lahaye M, Peuskens J, Naber D, Dilbaz N, Millet B, Franco MA, Rancans E, Turczynski J, Smeraldi E, Lara E, Neznanov NG. Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics. Expert Opin Pharmacother 2014, 15:593-603. 10.1517/14656566.2014.884071, 24491033.
57. Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010, 30:487-495. 10.1097/JCP.0b013e3181eeb600, 20814330.
58. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, Schooler NR. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010, 71:587-598. 10.4088/JCP.09m05564yel, 20492853.
59. Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008, 23:209-215. 10.1097/YIC.0b013e3282fce651, 18545059.
60. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm 2008, 65:403-413. 10.2146/ajhp070261, 18281731.
61. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994, 55:5-12.
62. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008, 197:229-235. 10.1007/s00213-007-1029-z, 18058087.
63. Schreiner A, Dilbaz N, Kotler M, Rosa F, Hoeben D, Paterakis P, Milanova V, Tessier C, Smulevich A. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral olanzapine 2010, Bejing, China: Poster presented at World Psychiatric Association Congress.
64. Schreiner A, Hoeben D, Lahaye M, Tzotzoras T, Louvrier J, Helldin L, Dilbaz N, Naber D, Dembinskiene L, Tessier C. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone 2010, Bejing, China: Poster presented at World Psychiatric Association Congress.
65. Tessier C, Hoeben D, Lahaye M, Bain-Bold KS, Millet B, Bagalà A, Franco M, Ivanov M, Georgiou G, Schreiner A. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral quetiapine 2010, Bejing, China: Poster presented at World Psychiatric Association Congress.
66. Schreiner A, Hoeben D, Lahaye M, Tessier C, Naber D, Peuskens J, Vauth R, Jasovic-Gasic M, Rancans E, Didi R. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral aripiprizole 2010, Bejing, China: Poster presented at World Psychiatric Association Congress.
67. World Health Organisation ATC/DDD Index 2012. http://www.whocc.no/atc_ddd_index/, World Health Organisation.
68. Heres S, Don L, Herceg M, Bidzan L, Blanc M, Siracusano A, Maciulis V, Lahaye M, Schreiner A. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use. Prog Neuropsychopharmacol Biol Psychiatry 2014, 48:207-212.
69. Schreiner A, Hoeben D, Tessier C, Lahaye M, Turczynski J, Vauth R, Millet B, Franco M, Sacchetti E. Tolerability and treatment responses in patients with recently diagnosed vs chronic schizophrenia treated with paliperidone ER 2011, Vienna, Austria: Poster presented at the 19th European Congress of Psychiatry (EPA).
70. Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L, Boom S, Kramer M, Eerdekens M. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010, 24:1011-1018. 10.1177/0269881109106914, 19825908.
71. Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry 2011, 11:21. 10.1186/1471-244X-11-21, 3045297, 21299844.
72. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999, 16:1514-1519. 10.1023/A:1015040217741, 10554091.
73. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol 2011, 7:829-846. 10.1517/17425255.2011.575061, 21476873.
74. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 2008, 69:18-31. 10.4088/JCP.0608e18, 18484805.
75. Vermier M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, Van Osselaer N, Cleton A. Absorption, metabolism, and excretion of paliperidone a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008, 36:769-779. 10.1124/dmd.107.018275, 18227146.
76. Kramer M, Simpson G, Maciulis V, Kushner S, Liu Y, Lim P, Hough D, Palumbo J, Eerdekens M. One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia. CNS Spectr 2010, 15:506-514.
77. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010, 13:635-647. 10.1017/S1461145709990988, 19941696.